Skip Navigation

FDA Warns 3 Million FreeStyle Libre 3 and Libre 3 Plus Sensors Impacted by Massive Abbott Recall

FDA Warns 3 Million FreeStyle Libre 3 and Libre 3 Plus Sensors Impacted by Massive Abbott Recall

Federal regulators have announced a Class I recall of approximately 3 million Abbott FreeStyle Libre 3 and Libre 3 Plus continuous glucose monitor sensors, following multiple deaths associated with inaccurate readings.

The U.S. Food and Drug Administration (FDA) announced the Abbott FreeStyle Libre 3 recall on January 15, after receiving more than 700 reports of serious health events linked to sensors that displayed falsely low glucose readings, creating a risk of improper insulin dosing, loss of consciousness, emergency medical intervention, and other potentially life-threatening complications.

Glucose monitor sensors are wearable devices, typically placed on the upper arm, that provide continuous readings of blood sugar levels. They play an essential role for people with diabetes by offering real-time information that helps guide insulin use, diet and daily activity to prevent dangerous glucose fluctuations.

According to an Abbott recall originally announced by the manufacturer on November 24, internal testing has revealed that some FreeStyle Libre 3 sensors may display inaccurately low glucose readings for prolonged periods without alerting users.

These false readings have led to a growing number of Abbott Libre 3 lawsuits, which claim the sensor defect could prompt unnecessary insulin use, increasing the risk of severe hypoglycemia, disorientation, fainting and other serious health emergencies.

FreeStyle-Libre-3-Recall-Lawsuit
FreeStyle-Libre-3-Recall-Lawsuit

Abbott says that it has received at least 736 worldwide reports of serious adverse events linked to problems with the FreeStyle Libre 3 system, including 57 cases in the U.S. The company also indicates that at least seven deaths may be associated with complications stemming from inaccurate low glucose readings.

The FDA Class I recall affects an estimated 3 million FreeStyle Libre 3 and Libre 3 Plus sensors, although the manufacturer says that roughly half of those units have already been used or have expired. Consumers are being directed to check whether their sensor is included in the recall by visiting www.FreeStyleCheck.com, where they can also request a replacement.

Class I recalls are the most serious type of recall, which indicate that the FDA has determined use of the product poses a reasonable probability of serious injury or death.

The current recall does not apply to Libre 3 readers, any of the related mobile applications, or other Libre-branded products, including the FreeStyle Libre 14 Day, FreeStyle Libre 2, FreeStyle Libre 2 Plus or Libre Pro sensors.

Abbott is advising anyone currently using an affected sensor to immediately stop and properly discard the device. The company states it has identified and corrected the underlying issue and continues to manufacture Libre 3 and Libre 3 Plus sensors to meet replacement needs and fulfill new orders. Users are also encouraged to rely on a traditional blood glucose meter, or the built-in meter in the Libre 3 reader, when sensor readings do not align with symptoms or expectations.

Additional information is available through Abbott’s website, by contacting customer service at 1-833-815-4273, which is staffed seven days a week from 8 a.m. to 8 p.m. ET, or via live chat 24/7 at https://www.freestyle.abbott/us-en/support/contact-us.html.

This marks at least the second significant recall involving FreeStyle Libre devices in recent years. Abbott recalled approximately 4.2 million FreeStyle Libre glucose monitors in April 2023, after receiving more than 200 reports of batteries overheating, which were linked to fires and at least one reported burn injury.

FreeStyle Libre 3 Recall Lawsuits

In the wake of the recall, attorneys are reviewing FreeStyle Libre 3 lawsuits on behalf of individuals who suffered serious injuries or wrongful death after relying on falsely low glucose readings.

Individuals may be eligible to pursue a claim if they or a loved one used a recalled FreeStyle Libre 3 or Libre 3 Plus sensor and experienced any of the following severe health complications:

  • Wrongful death
  • Extreme hypoglycemia
  • Seizures
  • Confusion or altered mental status
  • Loss of consciousness
  • Diabetic ketoacidosis
  • Other acute metabolic emergencies
  • Hospitalization

Free case evaluations are available to help determine whether an Abbott FreeStyle Libre 3 lawsuit may be appropriate. An attorney can review the circumstances, explain potential legal options and assess whether a claim may be pursued.

Sign up for more health and legal news that could affect you or your family.

Written By: Michael Adams

Senior Editor & Journalist

Michael Adams is a senior editor and legal journalist at AboutLawsuits.com with over 20 years of experience covering financial, legal, and consumer protection issues. He previously held editorial leadership roles at Forbes Advisor and contributes original reporting on class actions, cybersecurity litigation, and emerging lawsuits impacting consumers.



0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

A Michigan couple has filed a Brookstone fire pit lawsuit, indicating the wife suffered severe burn injuries due to the product’s design and refueling instructions.
Nitrous oxide injury lawsuits are emerging as medical evidence links recreational use of the gas to nerve damage that can cause numbness, balance problems and difficulty walking, often without adequate side effect warnings.
A federal judge has scheduled a series of Bard PowerPort trials between April 2026 and February 2027, which will focus on allegations that defective design flaws made the devices susceptible to infections, fractures and migration.

About the writer

Michael Adams

Michael Adams

Michael Adams is a senior editor and legal journalist at AboutLawsuits.com with over 20 years of experience covering financial, legal, and consumer protection issues. He previously held editorial leadership roles at Forbes Advisor and contributes original reporting on class actions, cybersecurity litigation, and emerging lawsuits impacting consumers.